Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males

Conclusion No clinically meaningful interactions were observed between luseogliflozin and six commonly used OADs in Japan, although there were some changes in the pharmacokinetics of pioglitazone co-administered with luseogliflozin and for luseogliflozin co-administered with miglitol or pioglitazone. Funding Taisho Pharmaceutical Co., Ltd.

http://link.springer.com/10.1007/s12325-015-0209-1

Source: Advances in Therapy - May 15, 2015 Category: Drugs & Pharmacology Source Type: research